VIRMA and chronic myelogenous leukemia, BCR-ABL1 positive: They developed Rucaparib, a novel anticancer drug that inhibits KIAA1429 expression, suppressing CML cell proliferation, promoting apoptosis and increasing sensitivity to imatinib.